Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Theralase Technologies Inc. V.TLT.W


Primary Symbol: V.TLT Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

Recent & Breaking News (TSXV:TLT)

Theralase Files Health Canada Approval for Next Generation Therapeutic Laser

TheNewsWire February 9, 2015

Theralase Anti-Cancer Technology Research Accepted for Peer Reviewed Publication

TheNewsWire February 3, 2015

Theralase's Latest Research on Anti-Cancer Technology Accepted for Presentation at International Conference

TheNewsWire January 29, 2015

Theralase Files US Patent Application for Increased Targeting of Photo Dynamic Therapy

TheNewsWire January 20, 2015

Microcap Report: Theralase Tech. (V.TLT) active on cancer drug news

Stockhouse Editorial January 15, 2015

Theralase (V.TLT) names lead photo dynamic compound for human clinical cancer trials

Stockhouse Editorial January 15, 2015

Theralase Identifies Lead Photo Dynamic Compound for Human Clinical Trials

TheNewsWire January 15, 2015

Theralase to Present at Alpha North Investor Conference

TheNewsWire January 13, 2015

Theralase Summarizes its 2014 Scientific Achievements and 2015 Strategic Objectives

TheNewsWire January 9, 2015

Theralase Anti-Cancer Technology Picks Up Steam

Accesswire January 6, 2015

Theralase (V.TLT) celebrates positive test results from revolutionary bladder cancer treatment

Stockhouse Editorial December 23, 2014

Theralase Reports Results of PDC Therapy of Bladder Cancer in Orthotopic Rat Model

TheNewsWire December 23, 2014

Brian C. Wilson Joins Theralase Medical and Scientific Advisory Board

TheNewsWire December 16, 2014

University of Toledo Validates University Health Network In-Vitro Data

TheNewsWire December 9, 2014

Dr. Michael A. O'Donnell Joins Theralase Medical and Scientific Advisory Board

TheNewsWire December 3, 2014

Dr. Ashish M. Kamat Joins Theralase Medical and Scientific Advisory Board

TheNewsWire December 2, 2014

Theralase Releases 3Q2014 Financials

TheNewsWire November 28, 2014

Theralase Releases Annual General Meeting Video

TheNewsWire November 25, 2014

Theralase Technologies (V.TLT) active on cancer compound results

Stockhouse Editorial November 12, 2014

Theralase (V.TLT) further demonstrates phenomenal cancer immunity response in testing

Gaalen Engen November 12, 2014